Brokerages Set $23.67 Target Price for Tocagen Inc (TOCA)
Shares of Tocagen Inc (NASDAQ:TOCA) have received a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokerages have set a one year consensus target price of $23.67 for the company, according to Zacks. Zacks has also assigned Tocagen an industry rank of 111 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th.
Shares of Tocagen (NASDAQ TOCA) traded down $0.88 on Friday, hitting $11.00. The stock had a trading volume of 1,420,000 shares, compared to its average volume of 220,876. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07. Tocagen has a one year low of $8.60 and a one year high of $17.95.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.02). The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. equities analysts expect that Tocagen will post -2.88 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Brokerages Set $23.67 Target Price for Tocagen Inc (TOCA)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/17/brokerages-set-23-67-target-price-for-tocagen-inc-toca.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.